Botulinum Toxin in Urology
The minimally invasive use of botulinum toxin (BoNT) in the lower urinary tract has revolutionized the treatment of debilitating bladder, urethra, and prostate conditions refractory to conventional therapy. This is the first book focusing on the pra
- PDF / 6,180,522 Bytes
- 214 Pages / 439.37 x 666.142 pts Page_size
- 51 Downloads / 195 Views
Michael B. Chancellor • Christopher P. Smith
Botulinum Toxin in Urology
Authors Dr. Michael B. Chancellor Department of Urology Oakland University, Willam Beaumont School of Medicine Royal Oak, MI 48073 USA [email protected]
Dr. Christopher P. Smith The Scott Department of Urology Baylor College of Medicine Houston, TX 77030 USA [email protected]
ISBN 978-3-642-03579-1 e-ISBN 978-3-642-03580-7 DOI 10.1007/978-3-642-03580-7 Springer Heidelberg Dordrecht London New York Library of Congress Control Number: 2011928409 © Springer-Verlag Berlin Heidelberg 2011 This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilm or in any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from Springer. Violations are liable to prosecution under the German Copyright Law. The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. Product liability: The publishers cannot guarantee the accuracy of any information about dosage and application contained in this book. In every individual case the user must check such information by consulting the relevant literature. Cover design: eStudioCalamar, Figueres/Berlin Printed on acid-free paper Springer is part of Springer Science+Business Media (www.springer.com)
Foreword
Europe, North America and Asia Professor Christopher Chapple Dear Colleagues, I would like to congratulate Michael Chancellor and Christopher Smith on this very interesting overview of the use of botulinum toxin in the treatment of urological disorders. It is now clearly recognised that as a biological agent, the various formulations of botulinum toxin differ markedly in terms of their content, potency and potential site of action. There is no adequately controlled comparative data currently available contrasting one formulation of botulinum toxin with another. Most of the evidence base relating to the utilisation of botulinum toxin is from studies using onabotulinumtoxinA. We have phase II dose ranging data for onabotulinumtoxinA in idiopathic detrusor overactivity and phase III data with its use in the treatment of neurogenic detrusor overactivity in both multiple sclerosis patients and spinal cord injury patients recently reported at international meetings. This excellent overview comprehensively covers safety and general principles, aetiology and aspects of potential mechanisms of action and looks at the use of treatment for bladder, prostate and pelvic floor disorders. In addition there are interesting sections on the role of
Data Loading...
